Stock Groups

Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News By Investing.com

by Mike Robinson

[ad_1]

© Reuters

Geoffrey Smith 

Investing.com — Covid-19 shares fell in premarket trading Friday due to fears that Merck’s new experimental treatment for the disease may severely impact future demand. 

By (8:45 AM ET 1345 GMT), Moderna Stocks of (NASDAQ:), BioNTech and Ripple were down by 4.9% each, respectively Pfizer Stocks of (NYSE:) were down 1.9%.  Pfizer is the most price sensitive to news about vaccines because of its many revenue streams. The other two, however, are pure play on Covid-19 treatments. 

Merck (NYSE 🙂 stated earlier that an early stage trial of the experimental pill led to clear decreases in hospitalizations. The sample had all taken it after experiencing moderate Covid-19 symptoms. 

As is the norm when experimental drugs show signs of effectiveness, the study was terminated early.

Scientists are searching feverishly to find a Covid-19 treatment that is easy to manufacture, distribute and administer at large scale. A pill like this could change the status of millions of poorer nations, where Covid-19’s spread is still unassisted due to lack of vaccines. 

 

 

 

 

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]